Icecure Medical is trading 5.35% down now at $1.77 amid elevated Treasury yields and renewed inflation concerns.

  • No new company-specific announcement was identified on September 24, 2026; the latest major release remains the September 10 China regulatory approval for ProSense.
  • Broader risk sentiment weakened as investors focused on elevated interest rates, resilient economic data, and inflationary pressure.
  • The move is best attributed to global macro conditions rather than company-specific news.